BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 8951675)

  • 1. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
    Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
    J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
    Sharif NA; Xu SX; Miller ST; Gamache DA; Yanni JM
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
    Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
    Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis.
    Sharif NA; Xu SX; Yanni JM
    J Ocul Pharmacol Ther; 1996; 12(4):401-7. PubMed ID: 8951676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.
    Yanni JM; Miller ST; Gamache DA; Spellman JM; Xu S; Sharif NA
    Ann Allergy Asthma Immunol; 1997 Dec; 79(6):541-5. PubMed ID: 9433371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
    Beauregard C; Stephens D; Roberts L; Gamache D; Yanni J
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):315-20. PubMed ID: 17803429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of olopatadine and selected antihistamines with model and natural membranes.
    Brockman HL; Momsen MM; Knudtson JR; Miller ST; Graff G; Yanni JM
    Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use.
    Yanni JM; Stephens DJ; Parnell DW; Spellman JM
    J Ocul Pharmacol; 1994; 10(4):665-75. PubMed ID: 7714410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.
    Cook EB; Stahl JL; Barney NP; Graziano FM
    Ann Allergy Asthma Immunol; 2001 Nov; 87(5):424-9. PubMed ID: 11730187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
    Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B
    Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of (Z)-11-[3-(dimethylamino) propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride on experimental allergic conjunctivitis and rhinitis in rats and guinea pigs.
    Kamei C; Sugimoto Y; Nakamura S; Zhong C
    Arzneimittelforschung; 1995 Sep; 45(9):1005-8. PubMed ID: 7488300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
    Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
    Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.
    Ohmori K; Hasegawa K; Tamura T; Miyake K; Matsubara M; Masaki S; Karasawa A; Urayama N; Horikoshi K; Kajita J; Hasegawa M; Taniguchi K; Komada T; Kawamoto Y
    Arzneimittelforschung; 2004; 54(12):809-29. PubMed ID: 15646365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
    Galatowicz G; Ajayi Y; Stern ME; Calder VL
    Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat.
    Schoch C
    Ocul Immunol Inflamm; 2005 Feb; 13(1):39-44. PubMed ID: 15804768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
    Rosenwasser LJ; O'Brien T; Weyne J
    Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
    Leonardi A; Quintieri L
    Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine.
    Lytinas M; Kempuraj D; Huang M; Kandere K; Boucher W; Letourneau R; Jeudy S; Fitzgerald K; Spear K; Athanasiou A; Theoharides TC
    Allergy Asthma Proc; 2002; 23(1):45-51. PubMed ID: 11894734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
    Abelson MB; Spitalny L
    Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
    Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
    Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.